Form 4: Longeveron Inc. Grants 109,000 Stock Options to Chief Scientific Officer Joshua Hare

Longeveron Inc. has granted 109,000 stock options to its Chief Scientific Officer, Director, and 10% Owner, Joshua Hare, with an exercise price of $1.47, vesting quarterly over three years starting October 1, 2025.

Summary

• Joshua Hare, Chief Scientific Officer, Director, and 10% Owner of Longeveron Inc. (LGVN), was granted 109,000 stock options.
• The options have an exercise price of $1.47 per share.
• The grant date for these options was July 15, 2025.
• The options will expire on July 15, 2035.
• Vesting will occur quarterly over a three-year period, commencing on October 1, 2025.
• Following this transaction, Joshua Hare directly beneficially owns 109,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for retention and alignment of interests, indicating confidence in the executive's continued contribution and the company's future prospects. It's a standard compensation practice.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer aligns management's interests with shareholder value creation, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the executive.
• The vesting schedule over three years encourages retention and sustained performance from a key scientific leader.

Negatives

• The exercise price of $1.47 is relatively low, which could suggest the company's stock price is currently low or that the options are intended to be 'in the money' quickly if the stock appreciates.
• Potential for dilution if all options are exercised in the future, though this is standard for option grants.

Risks

• The value of the stock options is contingent on the future performance of Longeveron Inc.'s stock price; if the stock price does not exceed the exercise price of $1.47, the options may not be exercised.
• Future dilution of existing shares if the options are exercised.

Future Outlook

The stock options granted to Joshua Hare will vest quarterly over a three-year period beginning October 1, 2025, indicating a long-term incentive structure for the Chief Scientific Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, particularly for companies like Longeveron Inc. that are often in development stages and rely on long-term scientific leadership. Such grants aim to align the interests of key scientific personnel with the long-term success and innovation of the company.

Comparison to Industry Standards

• The grant of stock options to a Chief Scientific Officer is a standard practice in the biotech industry, comparable to compensation structures seen at companies like Moderna, BioNTech, or smaller clinical-stage biotechs, where attracting and retaining top scientific talent is crucial.
• The 10-year expiration period is typical for employee stock options, providing a long window for value realization, similar to grants at companies such as Gilead Sciences or Amgen.
• The three-year quarterly vesting schedule is also a common industry standard for executive equity incentives, designed to ensure long-term commitment and performance, mirroring practices at firms like Vertex Pharmaceuticals or Regeneron Pharmaceuticals.

Related Party Transactions

• The grant of 109,000 stock options to Joshua Hare, who is a Director, 10% Owner, and Chief Scientific Officer, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize the Chief Scientific Officer to drive company growth and stock price appreciation.
• Employees: May signal stability and long-term commitment from key leadership, potentially boosting morale.
• Management: Provides a significant long-term incentive and aligns their financial interests with the company's performance.

Next Steps

• Continued vesting of the 109,000 stock options quarterly over the next three years, starting October 1, 2025.
• Potential exercise of options by Joshua Hare if the stock price exceeds $1.47 before July 15, 2035.

Key Dates

Recommendation

Keywords

Longeveron Inc., LGVN, Stock Options, Joshua Hare, Chief Scientific Officer, Director, 10% Owner, SEC Form 4, Executive Compensation, Equity Grant, Beneficial Ownership